You just read:

Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis

News provided by

ProMetic Life Sciences Inc.

Sep 25, 2017, 06:30 ET